ClinicalTrials.gg
Enrolling by invitationNCT07846501Updated Sep 29, 2026

The Role of Pain Catastrophizing, Resilience, and Illness Perception in Predicting Fibromyalgia Impact in Patients With Fibromyalgia

An observational study in Fibromyalgia, sponsored by Bilecik Seyh Edebali Universitesi. Enrolling by invitation at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Bilecik Seyh Edebali Universitesi · Observational

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 195 studies in Fibromyalgia with a site in Turkey — 51 open to participants now, 55 under way, none of them phase 3. Fibromyalgia · Turkey.

Planned enrollment
17th of 91
150 · median 100
Started
2026
with 24 others
Observational
91 of 195
25 open now
Primary completion
2027-06
later than 47 of 54 live
Registered
188th of 195
by date

Among the 195 studies in Fibromyalgia with a site in Turkey, this one is the 17th largest by planned enrollment of the 91 observational ones that give a count, is one of 25 that started in 2026, is one of 91 observational ones, reaches primary completion later than 47 of the 54 other live ones, and was the 188th registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

51 of the 195 studies in Fibromyalgia with a site in Turkey are open now. Recruiting first, the newest first:

46 more — sign in →

All 51 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 195 studies in Fibromyalgia with a site in Turkey, or all of them as a file.
02

Study summary

This study aims to reveal the effects of pain catastrophizing, psychological resilience, and illness perception on the impact level of fibromyalgia in patients with fibromyalgia, to determine the predictive power of these psychosocial variables regarding the impact level of fibromyalgia, and to evaluate their roles in explaining the burden of the disease.

Read the detailed description

While pain catastrophizing, resilience, and illness perception have been examined separately in patients with fibromyalgia, studies evaluating the extent to which these variables collectively predict the impact of the disease are limited. Addressing pain catastrophizing and negative illness perception as risk factors, alongside resilience as a protective factor, within a single model will contribute to a more holistic explanation of the disease burden experienced by fibromyalgia patients. The results of this study are expected to enhance the understanding of the psychosocial factors that determine the impact of the disease on fibromyalgia patients. Furthermore, the findings are anticipated to provide a scientific basis for the development of psychoeducation, cognitive-behavioral counseling, resilience-supporting interventions, and individualized care plans by nurses and other healthcare professionals. In this regard, the study will contribute to strengthening the biopsychosocial approach to fibromyalgia management and to the planning of patient-centered care practices.

03

Conditions studied

  • Fibromyalgia

Browse trials for

Keywords

  • Fibromyalgia
  • Resilience Perception
  • Pain Catastrophizing
  • Illness Perception
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with fibromyalgia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with fibromyalgia,
  • Aged 18 years or older,
  • Literate in Turkish,
  • And without communication difficulties.

Exclusion criteria

Exclusion Criteria:

  • Those with a disease causing cognitive impairment who are unable to answer the survey questions,
  • Those with chronic painful medical conditions other than fibromyalgia (e.g., migraine, diabetic neuropathy, rheumatoid arthritis, etc.),
  • Those diagnosed with neurocognitive, mental, or emotional disorders,
  • Patients with multisystemic diseases such as cancer.
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
150 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Visual Analog Scale

    VAS (Visual Analog Scale): A scale consisting of a 10 cm horizontal line marked at equal intervals, with one end representing "no pain" and the other "unbearable pain." The patient is asked to mark the point on the line that best represents the intensity of their pain. This distance, measured in millimeters, is interpreted as a "score." Regarding pain intensity, a score of 0 is rated as "no pain," while a score of 10 is rated as "unbearable, worst possible pain."

    Time frame: 1 days

  2. Revised Fibromyalgia Impact Questionnaire

    Revised Fibromyalgia Impact Questionnaire (FIQR): This questionnaire was updated by Bennett et al. in 2009. It consists of 21 separate questions, all rated on a scale of 0 to 10; a score of 10 represents the worst possible state, while 0 indicates the absence of the complaint. The questionnaire comprises three sub-dimensions: "function" (9 questions), "overall impact" (2 questions), and "symptoms" (10 questions). The total score for function (range 0-90) is divided by 3, the total score for overall impact (range 0-20) remains unchanged, and the total score for symptoms (range 0-100) is divided by 2. The total questionnaire score (0-100) is the sum of these values. A higher score indicates a high level of impact from the disease. The recommended cut-off points for disease severity are as follows: 0-23, remission; 24-40, mild disease; 41-63, moderate disease; 64-82, severe disease; and 83-100, very severe disease. The Cronbach's alpha for the FIQR is 0.95, and item-total correlations ra

    Time frame: 1 days

  3. The Pain Catastrophizing Scale

    The Pain Catastrophizing Scale is a 13-item self-report scale developed by Sullivan et al. to assess the extent to which individuals tend to catastrophize in response to pain; it utilizes a 5-point Likert-type rating system (scoring 0-4). The original form of the scale comprises three sub-dimensions: helplessness, magnification, and rumination. The internal consistency reliability of the Turkish adaptation of the Pain Catastrophizing Scale was found to be very high, with a Cronbach's alpha coefficient of 0.955. Item-total and inter-item correlation coefficients for the scale were determined to range between 0.488 and 0.848.

    Time frame: 1 days

  4. Brief Illness Perception Questionnaire

    Brief Illness Perception Questionnaire: Developed by Broadbent et al. in 2006. This scale comprises 8 items plus an additional item investigating causal factors. With the exception of the ninth item regarding causal factors, the eight items on the scale use a Likert-type scoring system ranging from 0 to 10. The first five items assess cognitive illness representations: consequences (Item 1), timeline (Item 2), personal control (Item 3), treatment control (Item 4), and identity (Item 5). Two items assess emotional illness perceptions: concern (Item 6) and emotions (Item 8). One item evaluates illness coherence (Item 7). Causal representation is assessed via an open-ended question asking patients to list the most important causal factors of their illness (Item 9). Scores on the scale indicate the perceived threat of the illness or the individual's level of ease regarding the condition. When calculating the score, the values for items 3, 4, and 7 are reversed and added to the scores of

    Time frame: 1 days

  5. Brief Resilience Scale

    Brief Resilience Scale: This scale was developed by Smith et al. (2008) to measure individuals' psychological resilience. It is a 6-item, self-report instrument using a 5-point Likert scale. Items 2, 4, and 6 are reverse-coded. After reversing the scores for these items, high total scores indicate a high level of psychological resilience. The internal consistency reliability of the Turkish adaptation of the scale was found to be .83.

    Time frame: 1 days

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2026
First posted
Sep 29, 2026
StartActual
Sep 16, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Sep 1, 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07846501
Lead sponsor
Bilecik Seyh Edebali Universitesi
Responsible party
Semanur Bilgiç (Research Assistant, Bilecik Seyh Edebali Universitesi) — Principal investigator
First posted
Sep 29, 2026
Start date
Sep 16, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Sep 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion